Solutions / Products more
News / News more
Fapon Biotech new reagent raw materials and test components for the latex-enhanced immunoturbidimetric platform is now added to the COVID-19/SARS-CoV-2 Neutralizing Antibody Test Solution. Products for ELISA, CLIA and CMIA, had introduced earlier in supporting customers’ NAb test development and vaccine effectiveness evaluation. With the company mission, ‘Enable Earlier Disease Identification, More Convenient, Accurate and Affordable Diagnosis’, continues to illuminate each action made during the pandemic, Fapon Biotech seeks ongoing innovations to support pandemic diagnosis and control. Curre...
Date: 2021 - 03 - 01
Fapon Biotech makes persist efforts to deal with the global pandemic new challenge, introduces COVID-19 Variant E484K POCT Solution for the effective differentiation of E484K and non-E484K infection. Previously, the company took a significant innovative step for being the first in the world in launching POCT Solution for variant B.1.1.7 (VUI 202012/01) and wild-type virus differentiation (https://bit.ly/3qDsmky). These solutions using POCT mechanism to offer additional values to the variant diagnosis using genome sequencing and PCR technologies, being an excellent mean to fight against the glo...
Date: 2021 - 02 - 19
Fapon Biotech is pleased to confirm the effective detection of its COVID-19 antibodies to the mainstream variants, B.1.1.7(also known as SARS-CoV-2 VUI 202012/01) and B.1.351 (known as 501Y.V2) after implemented evaluation using recombinant NP antigens.The evaluations showed the same reaction to wild-type strains, confirming the effective detection to COVID-19 variants and wild-type strains with no omission in test results.  Fapon Biotech has a strong position in the fight of COVID-19. Its antibody pairs have the best-in-class specificity, which had been widely used by global reagent manu...
Date: 2021 - 01 - 20
Fapon Biotech, a mainstream COVID-19 raw materials supplier to the global top-profile reagent manufacturers, introduced pioneering COVID-19 antibodies for antigen lateral flow testing to detect and differentiate COVID-19 and the most notable variant B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) in human samples.Variant strain surveillance is vital for COVID-19 control. Variants such as B.1.1.7 that causes 40-70% higher transmissibility and false-negative results on some PCR tests had drawn concerns and investigation from scientists and healthcare authorities like WHO, FDA and others. Accord...
Date: 2021 - 01 - 17
There are an estimated 1 billion flu cases annually around the world according to WHO. Giving the early symptoms manifested by flu and COVID-19 are similar, tests for differentiation will be significant to enable accurate diagnosis and treatment. With the possible COVID-19 resurgence in winter, demands for flu and COVID-19 testing will be jumped high in parallel. Health authorities and Dx companies already rolled out strategies and products in preparation for increasing needs of flu and COVID-19 testing. The Department of Health and Social Care of the UK has deployed new multip...
Date: 2020 - 09 - 30
Fapon Biotech Inc. (Fapon) announces the second COVID-19 donation to support the global pandemic battle with free Anti-SARS-CoV-2 Fully Human RBD IgM & IgG Quality Control Materials for the usage of 100 million tests. The first donation was initiated in quarter 1 to give 3 million PCR test components to solve the shortage of raw materials and test development challenges of global IVD partners.  The confirmed COVID-19 cases had exceeded 13 million with reagent manufacturers are ramping up antibody test production to massive scale per day. The antibody test is now not only applied to as...
Date: 2020 - 07 - 21
In April, WHO explicitly stated that rapid diagnostic antigen tests are best used to identify acute or early COVID-19 infection, whereas rapid diagnostic antibody tests are to be applied in disease surveillance and epidemiologic research. Now more and more government bodies had included antigen tests in their COVID-19 diagnostic strategies. European Centre for Disease Prevention and Control, Health Products Regulatory Authority of Ireland, Ministry of Health of Japan, The Indian Council of Medical Research noted that antigen test provides rapid...
Date: 2020 - 07 - 01
To address the unmet medical needs during this COVID-19 pandemic, Fapon once again manifests the strength of R&D capabilities to the world by being one of the leading biotechnology companies to launch the COVID-19 Naturalizing Antibodies Titer Testing Solution for ELISA and CLIA. This solution provides raw materials and quality controls to aid the evaluation of vaccine efficacy, antibody-drug effectiveness, convalescent plasma therapy, and seroepidemiological investigation. What is COVID-19 Neutralizing Antibodies  Neutralizing antibodies (NAbs) have significant preventive a...
Date: 2020 - 06 - 08